Ignite Planners LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Ignite Planners LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 75.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,023 shares of the company’s stock after purchasing an additional 871 shares during the quarter. Ignite Planners LLC’s holdings in Eli Lilly and Company were worth $915,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Silicon Valley Capital Partners purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $25,000. Bogart Wealth LLC grew its holdings in Eli Lilly and Company by 193.3% during the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after acquiring an additional 58 shares in the last quarter. Laffer Tengler Investments bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $33,000. Raleigh Capital Management Inc. increased its position in shares of Eli Lilly and Company by 156.4% in the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after purchasing an additional 61 shares during the last quarter. Finally, Tanglewood Legacy Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 34,156 shares of the firm’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total value of $15,509,556.48. Following the transaction, the insider now directly owns 101,387,286 shares in the company, valued at approximately $46,037,938,826.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Alonzo Weems sold 1,148 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The disclosure for this sale can be found here. Insiders sold 1,010,309 shares of company stock valued at $21,095,701,670 over the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several research reports. Barclays lifted their target price on Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 9th. HSBC started coverage on shares of Eli Lilly and Company in a research report on Friday, July 14th. They set a “buy” rating and a $560.00 price target for the company. Truist Financial boosted their target price on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $510.00 to $600.00 and gave the company an “overweight” rating in a report on Wednesday, August 9th. Finally, Bank of America raised their target price on Eli Lilly and Company from $500.00 to $600.00 in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $532.78.

Eli Lilly and Company Stock Down 0.5 %

Shares of LLY traded down $2.61 during trading hours on Monday, reaching $573.05. The company’s stock had a trading volume of 1,326,004 shares, compared to its average volume of 3,029,493. The firm has a market cap of $543.99 billion, a price-to-earnings ratio of 79.56, a P/E/G ratio of 2.44 and a beta of 0.32. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. The company has a 50 day moving average of $512.56 and a two-hundred day moving average of $439.28. Eli Lilly and Company has a 1-year low of $296.32 and a 1-year high of $601.84.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The business had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. During the same period last year, the company earned $1.25 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 9.84 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.